Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.50 |
| ▸ | JAK3 | P52333 | 4/20 | 0.50 |
| ▸ | JAK1 | P23458 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | BTK | Q06187 | 6/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | BLK | P51451 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19332684 | 1.00 | JAK2 (0.50) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL31693463 | 0.87 | JAK2 (0.67) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL19353358 | 0.84 | JAK2 (0.45) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL28829594 | 0.84 | JAK2 (0.45) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL29760783 | 0.84 | JAK2 (0.45) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL19250519 | 0.79 | ADORA2A (0.37) | JAK2JAK3JAK1EGFR | |
| SCHEMBL17770583 | 0.79 | JAK2 (0.77) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL19332896 | 0.78 | BTK (0.61) | JAK3EGFRBTKITKERBB2 | |
| SCHEMBL19332781 | 0.78 | BTK (0.61) | JAK3EGFRBTKITKERBB2 | |
| SCHEMBL2733327 | 0.74 | EGFR (0.77) | JAK2JAK3JAK1EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426637-B1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ANGEL PHARMACEUTICAL CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
| EP-3426637-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | Corvus Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017156495-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | JAK2 29/4885JAK3 110/4885JAK1 112/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | JAK2 29/4885JAK3 110/4885JAK1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.